Monopar Expands Radiopharma Intellectual Property Portfolio With Patent Filing On New Compounds and Linkers

Benzinga · 10/15 12:25

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101.

 

Highlights of the patent filing include:

  • Composition of Matter: Claims cover a family of linkers, as well as Monopar's uPAR targeting agents linked with these along with therapeutic radioisotopes
  • Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar's array of therapeutic radiopharmaceuticals
    • Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies